TY - JOUR T1 - ERAAs for menopause treatment: Welcome the ‘designer estrogens’ JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 463 LP - 470 DO - 10.3949/ccjm.84a.15140 VL - 84 IS - 6 AU - Heather D. Hirsch AU - Elim Shih AU - Holly L. Thacker Y1 - 2017/06/01 UR - http://www.ccjm.org/content/84/6/463.abstract N2 - Estrogen receptor agonist-antagonists (ERAAs) selectively inhibit or stimulate estrogen-like action in targeted tissues. This review summarizes how ERAAs can be used in combination with an estrogen or alone to treat menopausal symptoms (vasomotor symptoms, genitourinary syndrome of menopause), breast cancer or the risk of breast cancer, osteopenia, osteoporosis, and other female midlife concerns. ER -